<DOC>
	<DOCNO>NCT00491530</DOCNO>
	<brief_summary>The objective study ass continue safety daily coadministration ABT-335 combination rosuvastatin calcium , simvastatin atorvastatin calcium .</brief_summary>
	<brief_title>A Year 2 , Safety Extension Study Combination ABT-335 Statin Therapy Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Adult male female subject voluntarily sign informed consent . Subject successfully complete treatment phase precede openlabel year 1 study . Subject use use investigational medication , except approve Abbott . Subject prematurely discontinue his/her combination therapy administer precede openlabel year 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>